(Press-News.org) Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications. Although we have known about the disease for over a century and its genetic basis for almost 20 years, there was no effective treatment until now.
Kidneys stopped growing
"Our study highlights a potential treatment that reduces kidney growth and the associated symptoms and slows the decline in kidney function," explains Professor Olivier Devuyst from the Institute of Physiology at the University of Zurich – one of the chief researchers in the phase-three clinical trial just published in the New England Journal of Medicine.
Over 1,400 patients were given tolvaptan over a three-year period at 129 centers worldwide. The drug is a selective V2 vasopressin receptor antagonist that lessens the effect of the antidiuretic (urine-concentrating) vasopressin hormone and increases urination.
The researchers studied whether tolvaptan slows the progression of the kidney disease by slowing the cyst growth. "The study achieved its goal," explains Professor Devuyst. In patients who received tolvaptan for three years instead of the placebo, the entire kidney volume decreased with fewer complications resulting from the disease, the pain eased off and the decline in kidney function was slowed. Adverse events such as increased urination and thirst as well as increased liver enzymes and blood sodium level were apparent.
15-year research project
The study is the culmination of 15 years of research done by several research groups including that of Olivier Devuyst. They began by examining transport mechanisms in cells that coat the cysts and, in particular, identified the pathway of the V2 vasopressin receptor as a potential trigger for cystic kidney disease. The demonstration that blocking this receptor slows the disease and improves the kidney function in various animal models provided the rationale for the intervention study with tolvaptan.
###
Literature:
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, and Frank S. Czerwiec. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine. November 3, 2012. Online publication: NEJM.org.
The study was conducted in collaboration with the clinical research of the ADPKD at the University of Zurich's Institute of Physiology and the Clinic for Nephrology at University Hospital Zurich (PD Dr. Andreas Serra and Professor Rudolf Wüthrich). The research team at the Clinic for Nephrology looks after one of the largest groups of ADPKD patients in Europe in close collaboration with SwissPKD (Schweizer Gesellschaft polyzystischer Nierenerkrankung) (www.SwissPKD.ch).
Contact:
Prof. Olivier Devuyst
Institute of Physiology
University of Zurich
Tel. +41 44 635 50 82
E-Mail: olivier.devuyst@uzh.ch
Cystic kidney growth curbed
2012-11-05
ELSE PRESS RELEASES FROM THIS DATE:
US Hispanics at high risk for cardiovascular disease
2012-11-05
Hispanics and Latinos living in the U.S. are highly likely to have several major cardiovascular disease risk factors, such as high cholesterol, high blood pressure, obesity, diabetes, and smoking, according to a new, large-scale study. Risks vary among the diverse Hispanic/Latino groups, but individuals who were born in the U.S. are more likely to have multiple risk factors.
The findings are reported in the Nov. 7 issue of JAMA.
Hispanic and Latino people now comprise the largest minority group in the U.S. Although this population is relatively young, cardiovascular ...
New findings on gene regulation and bone development
2012-11-05
The patients have single short fingers (metacarpals) and toes (metatarsals) and can be restricted in growth due to a shortened skeleton. This hereditary disease is called brachydactyly type E (Greek for short fingers). Three years ago Dr. Philipp G. Maass from the research group of Professor Friedrich C. Luft at the Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC) in Berlin-Buch, has discovered an epigenetic mechanism, which, when dysregulated, causes this condition. ...
Grandfathers play a more prominent role
2012-11-05
Europeans spend much time with their grandchildren. And past 70, the grandfather takes the lead.
Norwegian sociologist Knud Knudsen sets great store by his grandchildren. In that respect, he is typical of the grandparents in Europe who are the subjects of his recent research.
"Europeans with grandchildren generally opt to spend a good deal of time with them," says 67-year-old Knudsen, who is professor of sociology at the University of Stavanger (UiS).
"And grandfathers appear to be more involved than before," he adds. In a new study, he found that grandmothers are ...
Prenatal testosterone levels influence later response to reward
2012-11-05
Philadelphia, PA, November 5, 2012 – New findings led by Dr. Michael Lombardo, Prof. Simon Baron-Cohen and colleagues at the University of Cambridge indicate that testosterone levels early in fetal development influence later sensitivity of brain regions related to reward processing and affect an individual's susceptibility to engage in behavior, that in extremes, are related to several neuropsychiatric conditions that asymmetrically affect one sex more than the other.
Although present at low levels in females, testosterone is one of the primary sex hormones that exerts ...
Inhibition of enzyme NOX4 prevents liver fibrosis
2012-11-05
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.
The researchers studied the function of a cytokine called transforming growth factor-beta (TGF-beta) in the pathophysiology of the liver, which is one of the main research lines of the Biological Clues of the Invasive and Metastatic Phenotype research group at the IDIBELL, leaded by Isabel Fabregat.
This paper is related with the processes of ...
Massive volcanic eruption puts past climate and people in perspective
2012-11-05
The largest volcanic eruption on Earth in the past millions of years took place in Indonesia 74,000 years ago and researchers from the Niels Bohr Institute can now link the colossal eruption with the global climate and the effects on early humans. The results are published in the scientific journal Climate of the Past.
The volcano Toba is located in Indonesia on the island Sumatra, which lies close to the equator. The colossal eruption, which occurred 74,000 years ago, left a crater that is about 50 km wide. Expelled with the eruption was 2,500 cubic kilometers of lava ...
Crystals for efficient refrigeration
2012-11-05
Washington, D.C.--Researchers at the Carnegie Institution have discovered a new efficient way to pump heat using crystals. The crystals can pump or extract heat, even on the nanoscale, so they could be used on computer chips to prevent overheating or even meltdown, which is currently a major limit to higher computer speeds. The research is published in the Physical Review Letters.
Ronald Cohen, staff scientist at Carnegie's Geophysical Laboratory and Maimon Rose, originally a high school intern now at the University of Chicago carried out the research. They performed ...
More mobility – Due to deafferentation
2012-11-05
In the 'Journal of Neuroscience' (DOI:10.1523/JNEUROSCI.5912-11.2012) the researchers present the results of their study, showing how a local anesthetic can distinctly improve the motor skills of patients after a stroke.
"Many stroke patients suffer from chronic impairment of the hand or of the complete arm," Professor Dr. Thomas Weiss explains. Together with expert colleagues the psychologist of the department of Biological and Clinical Psychology at Jena University has been working for a number of years on a specialized medical training therapy which clearly enhances ...
Researchers make strides toward selective oxidation catalysts
2012-11-05
Oxide catalysts, typically formulated as powders, play an integral role in many chemical transformations, including cleaning wastewater, curbing tailpipe emissions, and synthesizing most consumer products.
Greener, more efficient chemical processes would benefit greatly from solid oxide catalysts that are choosier about their reactants, but achieving this has proven a challenge. Now researchers from Northwestern University and Argonne National Laboratory have developed a straightforward and generalizable process for making reactant-selective oxide catalysts by encapsulating ...
Scientists find Achilles’ heel of cancer cells
2012-11-05
Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.
In the cell, histone deacetylases (HDAC) are responsible ...